RAMP2

Across TCGA pan-cancer cohorts, RAMP2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RAMP2 data layer compared with 27 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher RAMP2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated RAMP2 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

PDAC, UCEC, and HNSC are the cancer types where RAMP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	II,III,IV	0.335	0.858	.010	6	view →
UCEC	DFS	Median	II,III,IV	0.515	0.925	.033	4	view →
HNSC	DFS	Quartile	IV	1.000	0.679	.024	4	view →
GBM	OS	Tertile	All	0.771	1.000	.018	2	view →
LSCC	OS	Tertile	All	0.923	1.000	.028	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RAMP2–PDAC (DFS)

Open the PDAC breakdown →